FDA Extends EYLEA HD Dosing Interval to 20 Weeks, Advancing Long-Term Retinal Care

Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with exte...

April 07, 2026 | Tuesday | News
Oncotelic Therapeutics Partners with TechForce Robotics to Commercialize AI-Driven GMP Robotics Platform

Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”), a clinical-stage biotechnology company focused on oncology and AI-dr...

April 03, 2026 | Friday | News
Thermo Fisher Scientific Launches Automated CTS Compleo System To Streamline Cell Therapy Fill And Finish

Thermo Fisher Scientific Inc., the world leader in serving science,  announced the global launch of the Gibco™ CTS™ Compleo™ Fill ...

April 03, 2026 | Friday | News
Reprogramming the Tumor: Lew Bender on Engineering a New Paradigm in Cancer Therapy

From a basement-born idea to a publicly traded biotech advancing late-stage clinical trials, Lew Bender’s journey reflects both scientific persistenc...

April 02, 2026 | Thursday | Interaction
Avacta Doses First Patient in FOCUS-01 Trial of AVA6103, Advancing Tumor-Targeted Oncology Platform

Enrollment underway in second Avacta clinical program at first three specialist U.S. oncology centers Initial data from the trial expected later this ye...

April 01, 2026 | Wednesday | News
Biocytogen Signs Platform License Agreement with Taisho Pharmaceutical

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and develo...

March 31, 2026 | Tuesday | News
Novartis to Acquire Excellergy in Up to $2 Billion Deal to Advance Next-Generation Allergy Therapies

Acquisition brings together Excellergy's differentiated trifunctional allergic effector cell response inhibitors (ECRIs) and the development expertise o...

March 30, 2026 | Monday | News
Continuity Biosciences and Breakthrough T1D Partner to Advance NICHE® Cell Therapy Platform Toward First-in-Human Study

Continuity Biosciences and Breakthrough T1D, the leading global type 1 diabetes (T1D) advocacy organization, today announced a strategic collaboration to...

March 26, 2026 | Thursday | News
Biocytogen and Moonlight Bio Partner to Advance Next-Generation Cell Therapies for Hard-to-Treat Cancers

-Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and devel...

March 25, 2026 | Wednesday | News
Cytiva and SR-TIGET Launch EU’s First Danaher Beacon to Advance Scalable Genomic Medicine

New “Danaher Beacon,” first in the European Union, aims to accelerate translation, scalability, and reliability across cell and gene therap...

March 25, 2026 | Wednesday | News
Belief BioMed’s Gene Therapy BBM-H901 Gains Macao Approval for Hemophilia B

Belief BioMed  announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the Pharmaceutical Adminis...

March 23, 2026 | Monday | News
Congruence Therapeutics Doses First Patient in Phase 1/1b Trial of MC4R Corrector CGX-926 for Genetic Obesity

Congruence Therapeutics  announced that the first participant has been dosed in its Phase 1/1b clinical trial evaluating CGX-926, an oral small-mole...

March 23, 2026 | Monday | News
TRIANA Doses First Patient in Phase 1/2 Trial of TRI-611, Advancing Molecular Glue Degrader Strategy in ALK+ NSCLC

TRI-611 is an oral investigational small molecule therapy designed as a potent, brain-penetrant molecular glue degrader, engaging the body’s in...

March 20, 2026 | Friday | News
Atrogi Advances First-in-Class “Exercise-Mimetic” ATR-258 into Human Trial for Muscle-Sparing Weight Loss

First-in-class oral therapy ATR-258 mimics the effects of exercise – driving fat loss, increasing muscle, and improving metabolism – with b...

March 19, 2026 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close